Replies to post #12686 on Hard to Treat Diseases (HTDS)

[2future4u]

Hard To Treat Diseases (HTDS) exclusive agent and partner of NCPC

SHENZHEN, China, Aug 11, 2009 /PRNewswire-FirstCall via COMTEX/ -- Hard to Treat Diseases, Inc. (HTDS:PK), (http://www.htdsmedical.com) subsidiary, Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) is pleased to announce that an agreement was reached between Mellow Hope and NCPC.

NCPC is the biggest modern Pharmaceutical manufacturer in China. http://www.ncpc.com.cn

In accordance with the agreement, Mellow Hope was appointed as the exclusive agent and partner of NCPC for its international marketing of Recombinant Hepatitis B Vaccine (CHO).

MARKET BACKGROUND

With the world's largest population and 17 million newborn babies each year, China is the world's fourth largest vaccine market. In China, vaccines represent a market worth over 3 billion RMB ($3.88 million), and this market is growing at 15% annually, reports Dr. Jianyuan Liu, associate director of National Vaccine and Serum Institute (NVSI) in the study, Advances in Biopharmaceutical Technology in China.1 Today, China has the largest vaccine manufacturing capabilities and capacity in the world. Dr. Liu and his colleagues also predict that China's vaccine market demand will rise to 20% in the next few years. Recent improvements in China's regulatory, market, and technology scenario are creating an optimistic outlook for its vaccine industry.

Large population, many newborns

China's population reached 1.3 billion in 2005 and will approach 1.4 billion in the next decade. The state has managed to control its birth rate to between 1.2% and 1.3%. Each year, approximately 17 million Chinese babies are born and all are suppose to receive vaccination. Based on this number, the following vaccine doses are needed each year for newborn babies:2

Poliomyelitis vaccine 68 million doses Diphtheria-pertussistetanus vaccine 68 million doses Hepatitis B vaccine 51 million doses Measles vaccine 34 million doses BCG vaccine 17 million doses

The aforementioned statistics and data were obtained from the following sources without permission

http://bioplanassociates.com (Direct link bellow)

http://bioplanassociates.com/publications/articles/VACCINES_China_Zhou_Apr07_C
hinaB.pdf


The HTDS management sees this agent agreement as a great potential boost of its revenue streams in introducing International marketing of Recombinant Hepatitis B Vaccine(CHO) to Mellow Hope's already existing distribution network.

In other company news, the company IP progress, Q2 financials and other corporate business matters are in the process of undergoing final review. These will be filed shortly and followed with an announcement.


YOU WROTE:

To that end, HTDS' Mellow Hope China based subsidiary has established a very close partnership with one of the biggest Pharmaceutical manufacturers in China. In this partnership, Mellow Hope acts as an exclusive agent and partner for its H1N1 Vaccine sales and marketing in the International markets. Up to today, the clinical trial of Influenza A (H1N1) Vaccine (Split Virion) through this Pharmaceutical manufacturer has been completed and approved. The H1N1 Vaccine manufacturing license will be granted soon. Again, due to confidentiality, competition, non disclosure, and other factors HTDS will not disclose the name of the Vaccine manufacturer in China until it obtains its manufacturing. HTDS future press releases and filings will address this.